Press Releases

Samsung BIO Insight

Samsung Biologics 2023 | Year in Review

Year_in_review_Samsung_Biologics.png
2023 was another eventful year for Samsung Biologics on its mission to create a better world and to support clients and the patients they serve with high quality biomedicines. Here’s a recap of the key highlights of the past year, and how we were able to positively shape the bio industry landscape.


Future of Biopharma
biocampus_2.png
Samsung Biologics announced further expansion of its biomanufacturing capacity, breaking ground on a fifth plant – the first facility of the company’s second Bio Campus. Bio Campus II will house Plants 5 through 8, for a total of 720,000 liters. Upon completion, expected in 2032, Samsung Biologics will boast over 1.3 million liters’ capacity, together with Plants 1 to 4 in Bio Campus I. This year also saw the completion of the company’s largest single manufacturing facility, Plant 4, which holds 240,000 liters’ capacity.

Related News


Increased Global Presence
SamsungBIologics_America.jpg
Samsung Biologics opened a regional office in New Jersey to streamline communication and enable the company to work in closer proximity to clients based in the U.S. and Europe, along with existing offices in San Francisco and Boston. The geographical expansion reflects Samsung Biologics’ commitment to anticipate and meet the needs of our clients, wherever they are located.

Related News


CDMO Partner of Choice
CDMO_Partner_of_Choice.png
Samsung Biologics had a busy year, expanding manufacturing pacts with multiple pharma giants, including Pfizer and Bristol-Myers Squibb. Samsung Biologics will produce biosimilar treatments in a range of therapeutic areas for Pfizer and manufacture a commercial antibody treatment for Bristol-Myers Squibb. Samsung Biologics has secured 14 of the top 20 global pharmaceutical companies as clients.

Related News


Strong Financial Standing
Strong_Financial_Standing.png
Buoyed by the near full utilization of all plants and increased partnerships with global biopharma, Samsung Biologics saw a year of record growth, posting consolidated revenue of over 1 trillion won in the third quarter. Among the new and expanded contracts this year, eight large-scale contracts were worth more than 100 billion won. Samsung Biologics expects the 2023 revenue to reach 3.6 trillion won, for an on-year increase of over 20 percent.

Related News


Investing in the Future
Investing_in_the_Future.jpg
Samsung Biologics continued to make investments in promising biotech companies through the Samsung Life Science Fund, as part of efforts to foster next-generation technologies. As the company is currently building its own antibody-drug conjugate (ADC) facility, Samsung Biologics made investments in Araris Biotech and Aimed Bio, both pioneering ADC-related technology. 

Related News


Bolstering CDO Capabilities
Bolstering%20CDO%20Capabilities.png
Building on a proven track record of success as a CDMO provider, Samsung Biologics optimized development services incorporating innovative processes and advanced proprietary platforms to accommodate clients’ evolving needs – supporting their journey from gene to investigational new drug and/or beyond. The company has packaged its drug development services into three programs – each designed to ensure maximum flexibility and meet the client’s goals per their development stage, while assessing potential risks.

Related News


Industry Trend-Setter
Industry_Trend_Setter.jpg
Samsung Biologics attended a series of global conferences and exhibitions this year, including BIO International, CPHI, DCAT, and J.P. Morgan Healthcare Conference. The company demonstrated how its services can accelerate clients’ drug journey and maximize the potential of their molecule. Samsung Biologics also consolidated its presence as a sustainable partner with an eco-friendly booth. The company also actively used the events to engage with existing and potential clients for future development and manufacturing pacts.

Related News


Prioritizing Sustainable Leadership
Prioritizing_Sustainable_Leadership.jpg
Samsung Biologics was awarded the Sustainable Markets Initiative’s Terra Carta Seal, becoming the first CDMO and the first Korean company to receive the Seal. The Terra Carta Seal, launched at the COP26, recognizes global companies that are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. It is awarded to companies whose ambitions are aligned with those of the Terra Carta, a recovery plan for Nature, People and Planet.

Related News


Advancing Global Decarbonization Targets
shutterstock_1652468917.jpg
Samsung Biologics believes the road to a net-zero supply chain starts from a grassroots engagement with its domestic partners. Samsung Biologics held its inaugural Supplier ESG Day at its headquarters to share ESG knowledge and guidance on decarbonization with its local suppliers. At the event, experts provided insights on ESG governance, while representatives from global suppliers presented case studies and tangible methods that local suppliers could apply to their operations.

Related News


Increased Global Recognition
Increased%20Global%20Recognition.png
At the CDMO Leadership Awards 2023, Samsung Biologics received the Champion Award in four categories – capabilities, compatibility, reliability, and quality - and the Excellence Award in all six categories. Samsung Biologics has won the awards for ten consecutive years. The award offers accurate customer feedback to provide support in choosing a reputable partner for development and manufacturing. Samsung Biologics was also recognized by Newsweek as one of the ‘World’s Most Trustworthy Companies’ for 2023.

Related News

Year_in_review_Samsung_Biologics.png
2023 was another eventful year for Samsung Biologics on its mission to create a better world and to support clients and the patients they serve with high quality biomedicines. Here’s a recap of the key highlights of the past year, and how we were able to positively shape the bio industry landscape.


Future of Biopharma
biocampus_2.png
Samsung Biologics announced further expansion of its biomanufacturing capacity, breaking ground on a fifth plant – the first facility of the company’s second Bio Campus. Bio Campus II will house Plants 5 through 8, for a total of 720,000 liters. Upon completion, expected in 2032, Samsung Biologics will boast over 1.3 million liters’ capacity, together with Plants 1 to 4 in Bio Campus I. This year also saw the completion of the company’s largest single manufacturing facility, Plant 4, which holds 240,000 liters’ capacity.

Related News


Increased Global Presence
SamsungBIologics_America.jpg
Samsung Biologics opened a regional office in New Jersey to streamline communication and enable the company to work in closer proximity to clients based in the U.S. and Europe, along with existing offices in San Francisco and Boston. The geographical expansion reflects Samsung Biologics’ commitment to anticipate and meet the needs of our clients, wherever they are located.

Related News


CDMO Partner of Choice
CDMO_Partner_of_Choice.png
Samsung Biologics had a busy year, expanding manufacturing pacts with multiple pharma giants, including Pfizer and Bristol-Myers Squibb. Samsung Biologics will produce biosimilar treatments in a range of therapeutic areas for Pfizer and manufacture a commercial antibody treatment for Bristol-Myers Squibb. Samsung Biologics has secured 14 of the top 20 global pharmaceutical companies as clients.

Related News


Strong Financial Standing
Strong_Financial_Standing.png
Buoyed by the near full utilization of all plants and increased partnerships with global biopharma, Samsung Biologics saw a year of record growth, posting consolidated revenue of over 1 trillion won in the third quarter. Among the new and expanded contracts this year, eight large-scale contracts were worth more than 100 billion won. Samsung Biologics expects the 2023 revenue to reach 3.6 trillion won, for an on-year increase of over 20 percent.

Related News


Investing in the Future
Investing_in_the_Future.jpg
Samsung Biologics continued to make investments in promising biotech companies through the Samsung Life Science Fund, as part of efforts to foster next-generation technologies. As the company is currently building its own antibody-drug conjugate (ADC) facility, Samsung Biologics made investments in Araris Biotech and Aimed Bio, both pioneering ADC-related technology. 

Related News


Bolstering CDO Capabilities
Bolstering%20CDO%20Capabilities.png
Building on a proven track record of success as a CDMO provider, Samsung Biologics optimized development services incorporating innovative processes and advanced proprietary platforms to accommodate clients’ evolving needs – supporting their journey from gene to investigational new drug and/or beyond. The company has packaged its drug development services into three programs – each designed to ensure maximum flexibility and meet the client’s goals per their development stage, while assessing potential risks.

Related News


Industry Trend-Setter
Industry_Trend_Setter.jpg
Samsung Biologics attended a series of global conferences and exhibitions this year, including BIO International, CPHI, DCAT, and J.P. Morgan Healthcare Conference. The company demonstrated how its services can accelerate clients’ drug journey and maximize the potential of their molecule. Samsung Biologics also consolidated its presence as a sustainable partner with an eco-friendly booth. The company also actively used the events to engage with existing and potential clients for future development and manufacturing pacts.

Related News


Prioritizing Sustainable Leadership
Prioritizing_Sustainable_Leadership.jpg
Samsung Biologics was awarded the Sustainable Markets Initiative’s Terra Carta Seal, becoming the first CDMO and the first Korean company to receive the Seal. The Terra Carta Seal, launched at the COP26, recognizes global companies that are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. It is awarded to companies whose ambitions are aligned with those of the Terra Carta, a recovery plan for Nature, People and Planet.

Related News


Advancing Global Decarbonization Targets
shutterstock_1652468917.jpg
Samsung Biologics believes the road to a net-zero supply chain starts from a grassroots engagement with its domestic partners. Samsung Biologics held its inaugural Supplier ESG Day at its headquarters to share ESG knowledge and guidance on decarbonization with its local suppliers. At the event, experts provided insights on ESG governance, while representatives from global suppliers presented case studies and tangible methods that local suppliers could apply to their operations.

Related News


Increased Global Recognition
Increased%20Global%20Recognition.png
At the CDMO Leadership Awards 2023, Samsung Biologics received the Champion Award in four categories – capabilities, compatibility, reliability, and quality - and the Excellence Award in all six categories. Samsung Biologics has won the awards for ten consecutive years. The award offers accurate customer feedback to provide support in choosing a reputable partner for development and manufacturing. Samsung Biologics was also recognized by Newsweek as one of the ‘World’s Most Trustworthy Companies’ for 2023.

Related News

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION